← All trials
NCT04576975
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 30, 2020
- Primary completion
- Dec 30, 2021
- Completion date
- Jul 1, 2022
- First posted
- Oct 6, 2020
- Last posted
- Oct 6, 2020
- Enrollment
- 30
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ain Shams UniversityLead sponsor
- Ain Shams UniversityReponsible party - principal investigator
- Government of KuwaitStudy director
- Government of KuwaitCollaborator
- Ain Shams UniversityStudy director
- Ain Shams UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.